[Primary hyperparathyroidism: From diagnosis to treatment].

Laure Carpentier, Benjamin Bouillet
{"title":"[Primary hyperparathyroidism: From diagnosis to treatment].","authors":"Laure Carpentier, Benjamin Bouillet","doi":"10.1016/j.revmed.2024.07.004","DOIUrl":null,"url":null,"abstract":"<p><p>Primary hyperparathyroidism (PHPT) is the leading cause of hypercalcemia. It is secondary to hypersecretion of parathyroid hormone (PTH) by the parathyroid glands. Today, PHTP is asymptomatic in 80-90% of cases. Its repercussions are mainly renal (nephrolithiasis, nephrocalcinosis, decline in renal function) and skeletal (osteoporosis, fractures), and should be systematically investigated. Diagnosis is only biological, and in its classic form relies on the association of hypercalcemia, inappropriate PTH (normal or elevated) and hypercalciuria. Diagnosis of normocalcemic forms, where only PTH is elevated, requires elimination of secondary hyperparathyroidism and confirmation of elevated PTH on two consecutive samples, over a 3 to 6 months period. Imaging evaluation, which combines neck ultrasound with scintigraphy or <sup>18</sup>F-choline PET/CT, is of interest only if surgery is indicated. Surgical management of the hyperfunctioning parathyroid gland(s) is the only curative treatment for HPTP. Medical management concerns patients for whom surgery is not indicated, who present a surgical contraindication or who refuse surgery. The diagnosis of HPTP warrants contact with an endocrinologist to ensure its management.</p>","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue de medecine interne","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.revmed.2024.07.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Primary hyperparathyroidism (PHPT) is the leading cause of hypercalcemia. It is secondary to hypersecretion of parathyroid hormone (PTH) by the parathyroid glands. Today, PHTP is asymptomatic in 80-90% of cases. Its repercussions are mainly renal (nephrolithiasis, nephrocalcinosis, decline in renal function) and skeletal (osteoporosis, fractures), and should be systematically investigated. Diagnosis is only biological, and in its classic form relies on the association of hypercalcemia, inappropriate PTH (normal or elevated) and hypercalciuria. Diagnosis of normocalcemic forms, where only PTH is elevated, requires elimination of secondary hyperparathyroidism and confirmation of elevated PTH on two consecutive samples, over a 3 to 6 months period. Imaging evaluation, which combines neck ultrasound with scintigraphy or 18F-choline PET/CT, is of interest only if surgery is indicated. Surgical management of the hyperfunctioning parathyroid gland(s) is the only curative treatment for HPTP. Medical management concerns patients for whom surgery is not indicated, who present a surgical contraindication or who refuse surgery. The diagnosis of HPTP warrants contact with an endocrinologist to ensure its management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[原发性甲状旁腺功能亢进症:从诊断到治疗]。
原发性甲状旁腺功能亢进症(PHPT)是导致高钙血症的主要原因。它继发于甲状旁腺分泌过多的甲状旁腺激素(PTH)。目前,80%-90%的 PHTP 病例没有症状。其影响主要是肾脏(肾结石、肾钙化、肾功能衰退)和骨骼(骨质疏松症、骨折),应进行系统的检查。诊断只是生物学上的,典型的诊断依赖于高钙血症、不适当的 PTH(正常或升高)和高钙尿。正常钙血症的诊断,即只有PTH升高,需要排除继发性甲状旁腺功能亢进,并在3至6个月内连续两次采样确认PTH升高。只有在有手术指征的情况下,才需要结合颈部超声和闪烁照相术或18F-胆碱PET/CT进行影像学评估。对功能亢进的甲状旁腺进行手术治疗是治愈 HPTP 的唯一方法。药物治疗适用于没有手术指征、有手术禁忌症或拒绝手术的患者。确诊为HPTP后,应与内分泌科医生联系,以确保治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[In patients with heart failure with preserved or mildly reduced ejection fraction, is finerenone effective in reducing a composite of heart failure exacerbation and cardiovascular death compared to placebo, and is it safe?] [The publications that change… the internist's Christmas eve]. [Human papillomavirus and systemic lupus erythematosus: A systematic review]. JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases. [Management of hepatic encephalopathy: A general review].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1